Prediction for major pathologic response after neoadjuvant tislelizumab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma by RNA sequencing: A single-arm, phase II trial.

• DOI: 10.1200/jco.2024.42.16_suppl.4078
• Publication Date: 2024-06-17T14:21:04Z
• Authors: Wei Guo; YingJian Wang; Yan He; Kunkun Li; Tao Bao; Xiandong He; Xianfeng Xie; Xv Chen; Xiangshu Pu
• Keywords: Neoadjuvant Therapy; Complete response

4078 Background: Although neoadjuvant chemoradiotherapy is evolved into standard-of-care treatment in locally advanced esophageal cancer (EC) patients (pts), nearly half of pts experience relapse and death within 5 years. It therefore important to establish novel effective strategies for further improve survival. With successful unresectable squamous cell carcinoma (ESCC) with PD-1/PD-L1 inhibitors, which are expected provide better benefits resectable ESCC preoperatively. However, owing lack predictors MPR immunotherapy, efficacy unsatisfactory. In this study we sought explore potential biomarkers tislelizumab combined chemotherapy Methods: single centre, perspective, arm study, 62 (stage II-IVA) were enrolled from January 2023 December. Pts received (200mg/ d1 Q3W) (Albumin Paclitaxel 240 mg/m2, Carboplatin: AUC=5 Q3W, or Nedaplatin: 70mg Q3W). Minimally invasive esophagectomy was performed 4-6 weeks after preoperative therapy. The primary endpoint rate secondary endpoints R0 resection rates adverse events (AEs). Exploratory biomarker analysis on tumor biopsy before Results: who all cycles plus 84% (52/62) whom proceeded surgery. Grade I AEs observed 57 (91.3%) most common anemia (49/62, 79%). 19 (30.6%) had grade II 4 (6.4%) III AEs. No higher observed. Reasons not undergoing surgery patient refusal (10/62, 16.1%). perioperative MPR, pCR (55.8%), (23.1%) (100%), respectively. mediate follow-up time 7.4 (1.7-12.6) months no found the last follow-up.10 underwent RNA-sequencing, achieved not. Compared pts, 393 upregulated 1950 downregulated genes non-MPR patients. Additionally, it indicated that immunomodulatory, keratinocyte differentiation calcium signaling pathway may correlate status by GSEA, GO KEGG analysis. Moreover, some hub genes, such as IL6, MMP1, SPPR3, CRNN, identified be associate Conclusions: Our results a feasibility option ESCC. addition, associated Further experimental studies needed investigate these findings. Clinical trial information: NCT05880082 .